Deramiocel Biologics License Application (BLA) under active FDA review HOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029 Cash, cash equivalents and marketable securities of approximately $238 million as of June 30, 2026 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (N...
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutic...
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an inv...
SAN DIEGO--(BUSINESS WIRE)-- #CAPR--Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors. What if I purchased Capricor securities? If you purchased Capricor securities and su...
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatme...
Shares of Capricor Therapeutics fell nearly 60% in premarket trading on Thursday after the U.S. FDA's panel of experts voted against the effectiveness data of its cell therapy for a heart condition related to Duchenne muscular dystrophy.
The U.S. FDA's panel of independent advisers on Wednesday voted against the benefits of Capricor Therapeutics' cell therapy, deramiocel, for treating cardiomyopathy in Duchenne muscular dystrophy, a rare muscle-wasting disease.